RTI Surgical Inc. (RTI) (Nasdaq: RTIX), a leading global surgical implant company, is launching two new biological solutions at the American Academy of Orthopaedic Surgeons (AAOS) annual meeting in New Orleans this week. NanOss ® Bioactive 3D, a synthetic three dimensional bioscaffold which supports bone formation, and map3 ™ Cellular Allogeneic Bone Graft, an implant that contains the three essential elements needed to generate and maintain new bone, will be introduced at the RTI Surgical exhibit at booth 5937 (Hall H) during the AAOS meeting.
map3 cellular allogeneic bone graft is a natural and safe alternative to autograft that supports the body's innate healing mechanisms and provides the scaffold and signals for neo-vascularization and bone growth (Photo: Business Wire)
“We are very excited to launch these two bone graft solutions,” said Brian K. Hutchison, president and chief executive officer of RTI Surgical. “NanOss Bioactive 3D, a synthetic bone graft, and map3 Cellular Allogeneic Bone Graft, a human tissue bone graft, showcase the broad portfolio of surgical implants offered by RTI Surgical.”
nanOss ® Bioactive 3D
The next-generation nanOss Bioactive 3D is an innovative solution that allows for precise placement of the graft into bony defects for a wide range of extremity and trauma surgical procedures. This advanced bone graft features a semi-rigid three dimensional scaffold consisting of porous hydroxyapatite granules suspended within a porous gelatin-based foam matrix, designed to support the body’s natural bone formation process. When hydrated, nanOss Bioactive 3D becomes formable and moldable allowing the implant to conform to the defect site. NanOss Bioactive 3D consists of nano-structured crystals which have extremely high surface area providing more cell attachment sites for osteoclasts and osteoblasts resulting in potential for improved mineralization, remodeling and bone formation.